Maxygen Inc (MAXY.W)
5.42USD
9 Feb 2010
$-0.14 (-2.52%)
$5.56
$5.42
$5.42
$5.42
700
149,561
$8.94
$4.78
MAXY.W
About
Overall
| Beta: | 0.78 |
| Market Cap (Mil.): | $207.26 |
| Shares Outstanding (Mil.): | 38.45 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| MAXY.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | -236.55 | -- | -- |
| ROI: | -18.55 | 1.25 | 2.30 |
| ROE: | -18.85 | 2.09 | 2.82 |
UPDATE 1-Maxygen, Astellas seal research pact, CEO will exit
SAN FRANCISCO, June 30 (Reuters) - Maxygen Inc , has agreed to set up a joint venture with Japan's Astellas Pharma Inc to focus on researching protein pharmaceuticals, as the U.S. drug maker brings in a partner to defray the cost of its research programs.
HEADLINE STOCKS-U.S. stocks on the move on Tuesday
NEW YORK, May 12 (Reuters) - Some U.S. stocks to watch on Tuesday:
HEADLINE STOCKS-U.S. stocks to watch on Tuesday
NEW YORK, May 12 (Reuters) - Some U.S. stocks to watch on Tuesday:
US RESEARCH SUMMARY-Non-S&P 500 Jan 30 2146 GMT
Following is a summary of research actions on non-S&P 500 companies reported
US RESEARCH SUMMARY-Non-S&P 500 Jan 30 1730 GMT
Following is a summary of research actions on non-S&P 500 companies reported
WRAPUP 1-Small drug developers cut jobs to save cash in crunch
* Small drug cos cut jobs, halt trials to preserve cash
HEADLINE STOCKS-Some U.S. stocks to watch on Nov. 5
The shares shed 24.1 percent to $2.58 in premarket trade on
UPDATE 1-Maxygen posts Q3 profit on sale of assets
Nov 4, 2008 (Reuters) - Biotechnology company Maxygen Inc
Wave of job cuts sweeps across corporate America
NEW YORK, Oct 23 (Reuters) - Corporate America is bleeding jobs and wielding the ax well beyond the financial sector.
UPDATE 1-Maxygen to explore strategic options, cut 30 pct jobs
Oct 22 (Reuters) - Biotechnology company Maxygen Inc said it would explore strategic options, plans to cut nearly 30 percent of its workforce and delay the late-stage manufacturing of its drug for a chemotherapy-induced blood disorder.
Competitors
| Price | Change | |
|---|---|---|
| Eli Lilly & Co. (LLY.N) | $35.20 | +0.42 |
| Pfizer Inc. (PFE.N) | $17.88 | +0.04 |
| Genentech, Inc. (DNA.N) | -- | -- |
| Bristol Myers Squibb Co. (BMY.N) | $24.25 | +0.29 |
| Bristol Myers Squibb Co. (BMY_p.N) | $439.50 | 0.00 |
| Schering-Plough Corporation (SGP.N) | -- | -- |
| Amgen, Inc. (AMGN.OQ) | $57.21 | -0.25 |
| Human Genome Sciences (HGSI.OQ) | $27.06 | +1.30 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | ₪21,350.00 | +140.00 |
| ZymoGenetics, Inc. (ZGEN.OQ) | $5.05 | -0.07 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
